3/ Receive hands-on training and 1:1 mentoring from international experts in scientific writing. Seats are limited and highly competitive, so apply now! 👉 Apply Here 🔗 More Details & Eligibility Criteria Additional Information:

4/ Additional Information: . No fee will be charged to selected participants. . ISN membership is required to apply, with a 50% discount available using code 50ISN24. . ISN membership provides access to the ISN Academy.

5/ . Selected participants will receive a contribution towards travel expenses. . Accommodation will be provided.

🚨 Last Chance! Apply for the Int Society of Nephrology Scientific Writing Course in North & East Asia, co-hosted by the Taiwan Society of Nephrology! New deadline: September 1! 🆓 No fee for selected participants 1/

✅ ISN membership required (50% off with code 50ISN24) 🌍 Travel & accommodation support available for eligible countries 2/

🎓 Certificate & post-course mentoring offered Apply now! reurl.cc/QE4vl5 #Nephrology #ISNSWC 3/

Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta-Analysis #CriticalCare #Sepsis #Bloodpurification journals.lww.com/ccmjournal/ful…

Kidney Week 2024 Kickoff!!

All set at the 2024 Annual Meeting of Taiwan Society of Nephrology (TSN) ! Thanks to Dr. Pei Chun Fan, Deputy Director of the TSN International Affairs and Cooperation Committee, and to Dr. Yu Ho Lee, Deputy Director of External Affairs and Cooperation Committee of the Korean Society of

EBM Series: Do CKD Patients Really Need Sodium Bicarbonate? 
A meta-analysis in CJASN explored the effects of Sodium Bicarbonate in CKD patients with metabolic acidosis (MA). 📊 Key findings

✅ Slows kidney function decline (eGFR ↑, p=0.03)
✅ Reduces hospitalization risk (-63%, p<0.001)
⚠️ Slightly increases BP risk, no impact on mortality Alkali therapy shows promise but requires precise patient selection!
Read more 👉journals.lww.com/cjasn/fulltext…

📍 Taipei, Taiwan, during #APCNxTSN2025 🗓️ December 2025 🔗 Apply here: lite.spr.ly/6003Gpkl

A large real-world study from TSN-EBM in Nature Communications explores GLP-1 RAs' effects in T2D patients with AKD: 📊 Key findings:
✅ Major adverse cardiac event ↓ 12%
✅ Major adverse kidney events ↓ 27% GLP-1 RAs show promising effects in diabetic AKD! 👉pubmed.ncbi.nlm.nih.gov/39003287/

Jonathan Barratt Adrian Liew International IgA Nephropathy Network 2025 Suceena Alexander Sydney Tang Vivekanand Jha | विवेकानन्द झा 📍 Taipei, Taiwan, during #APCNxTSN2025 🗓️ December 2025 🔗 Apply here: lite.spr.ly/6003Gpkl

Jonathan Barratt Adrian Liew International IgA Nephropathy Network 2025 Suceena Alexander Sydney Tang Vivekanand Jha | विवेकानन्द झा Taiwan Society of Nephrology (TSN) The Asian Pacific Society of Nephrology (APSN) Join/renew your ISN membership to access exclusive ISN educational initiatives. Please note that your membership must be active when the course takes place ➡️ theisn.org/membership/?ut…

We are pleased to announce the publication of the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Read the News Release: kdigo.co/NS-in-Children… Read the Guideline in Kidney International: kdigo.co/Nephrotic-Synd… Download the Guideline:

Welcome for submission to APCN x TSN 2025, to be hold in Taipei !!! apcn2025.org facebook.com/profile.php?id…

Can GLP-1 receptor agonists improve outcomes in CKD patients with eGFR < 60?
A new meta-analysis (AJKD 2025) of 17,996 patients says yes👇 ✅ ↓ Composite kidney outcome (OR 0.85)
✅ ↓ eGFR decline >30/40/50%
✅ ↓ All-cause mortality (OR 0.77) 🔗 doi.org/10.1053/j.ajkd…

TSN EBM Series vol.8—Do AKI ealerts change care?
JAMA Netw Open meta-analysis (13 studies; >40k):
↔ Mortality (RR 0.96)
✅ ↓ AKI progression (0.91)
✅ ↑ Nephrology consults (1.45) & AKI coding (1.28)
✅ ↓ NSAID exposure (0.75)
↔ LOS/costs
#EBM jamanetwork.com/journals/jaman…

TSN EBM vol. 9 - Earlier ACEI/ARB resumption after AKI? A cohort (n=5,392) study shows restarting at discharge or 0–3 mo vs 4–6 mo ↓ death (0.88/0.89), ↓ MACCE (0.84/0.88), ↓ new dialysis/ESRD (0.63/0.80), with no ↑ severe hyperK or reAKI. doi.org/10.1016/j.ekir…